Status:
RECRUITING
Impact of Metabolite Supplementation to Restore Mitochondrial Dysfunction During Septic Shock: a Preclinical Study
Lead Sponsor:
University Hospital, Angers
Conditions:
Septic Shock
Multiple Organ Failure
Eligibility:
All Genders
18+ years
Brief Summary
Septic shock is defined as a subset of sepsis with severe metabolism alterations, leading to organ failure. Septic shock is associated with a high mortality, around 40% according to the SEPSIS 3 defin...
Detailed Description
In this prospective study, the investigators will include patients admitted to the medical ICU of Angers University Hospital and meeting the SEPSIS-3 criteria for the definition of septic shock (Seque...
Eligibility Criteria
Inclusion
- All patients aged 18 or more
- Patients with criteria for septic shock according to SEPSIS 3 definition (presumed sepsis, with persisting hypotension requiring vasopressors to maintain mean arterial pressure \> 65 mmHg and having a serum lactate \> 2 mmol/L despite adequate fluid expansion).
- Admitted in the ICU of Angers University Hospital
Exclusion
- Minor patients (aged less 18)
- Patient subject to legal protection measures
- Refusal of the patient or his family
- Preexisting mitochondrial disease
- Patient with aplasia
- Pregnant or parturient women
Key Trial Info
Start Date :
July 9 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 9 2026
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT04288635
Start Date
July 9 2020
End Date
August 9 2026
Last Update
December 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU
Angers, Maine et Loire, France, 49933